Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in children with severe neurofibromatosis type 2
2021-005770-26Phase 2Active
- Sponsor
- Medical University of Warsaw
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in neurofibromatosis type 2 (NF2) and acoustic neuroma, sponsored by Medical University of Warsaw. Primary endpoint: Primary tumor stabilization or regression. Started Apr 2024; status: active.
02
Drugs
crizotinib
03
Conditions
neurofibromatosis type 2 (NF2)acoustic neuroma
Beyond the preview
Go deeper on 2021-005770-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005770-26.